QR код

Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study

Abstract Purpose Immunotherapy with atezolizumab and bevacizumab is the current first-line standard of care for unresectable hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and efficacy profile of atezolizumab-bevacizumab in the Indian population, as there are limited studies...

Повний опис

Збережено в:
Автори: Merin Babu, Ashok Sebastian Komaranchath, Arun Valsan, Arun R. Warrier, Rakesh MP, Wesley M. Jose, Nikhil K. Haridas, Sumi Soman, Manjima P. Nair, Shine Sadasivan, Abhinav Menon, Mohammed Thabrez, Keechilat Pavithran
Формат: Artigo
Мова:Inglês
Опубліковано: BMC 2025-07-01
Серія:BMC Cancer
Предмети:
atezolizumab
bevacizumab
hepatocellular carcinoma
real world
immune checkpoint inhibitors
Онлайн доступ:https://doi.org/10.1186/s12885-025-14400-9
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси